Show simple item record

dc.contributor.authorPrice, David
dc.contributor.authorHenley, William
dc.contributor.authorDelfini Cançado, José Eduardo
dc.contributor.authorFabbri, Leonardo M
dc.contributor.authorKerstjens, Huib AM
dc.contributor.authorPapi, Alberto
dc.contributor.authorRoche, Nicolas
dc.contributor.authorŞen, Elif
dc.contributor.authorSingh, Dave
dc.contributor.authorVogelmeier, Claus
dc.contributor.authorBarille, Sara
dc.contributor.authorNudo, Elena
dc.contributor.authorCarter, Victoria
dc.contributor.authorSkinner, Derek
dc.contributor.authorVella, Rebecca
dc.contributor.authorGeorges, George
dc.date.accessioned2022-02-16T14:42:01Z
dc.date.available2022-02-16T14:42:01Z
dc.date.issued2022-02-15
dc.identifier.citationPrice , D , Henley , W , Delfini Cançado , J E , Fabbri , L M , Kerstjens , H AM , Papi , A , Roche , N , Şen , E , Singh , D , Vogelmeier , C , Barille , S , Nudo , E , Carter , V , Skinner , D , Vella , R & Georges , G 2022 , ' Interclass difference in pneumonia risk in COPD patients initiating fixed dose inhaled treatment containing extrafine particle beclometasone versus fine particle fluticasone ' , International journal of chronic obstructive pulmonary disease , vol. 2022 , no. 17 , pp. 355—370 . https://doi.org/10.2147/COPD.S342357en
dc.identifier.issn1176-9106
dc.identifier.otherPURE: 212224368
dc.identifier.otherPURE UUID: 71cdea97-09f4-4be9-b5f4-3bdd94ad4e84
dc.identifier.otherScopus: 85125067641
dc.identifier.urihttps://hdl.handle.net/2164/18073
dc.descriptionAcknowledgements Professor Dave Singh is supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). Jaco Vooriham is acknowledged for his contribution to protocol development. We would also like to acknowledge Ms. Shilpa Suresh (MSc) of the Observational and Pragmatic Research Institute (OPRI), Singapore, for editorial and formatting assistance which supported the development of this publication.en
dc.format.extent16
dc.language.isoeng
dc.relation.ispartofInternational journal of chronic obstructive pulmonary diseaseen
dc.rightsThis work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.en
dc.subjectInhaled corticosteroidsen
dc.subjectpneumoniaen
dc.subjectCOPDen
dc.subjectExtrafine beclometasoneen
dc.subjectfluticasoneen
dc.subjectR Medicineen
dc.subjectSupplementary Informationen
dc.subject.lccRen
dc.titleInterclass difference in pneumonia risk in COPD patients initiating fixed dose inhaled treatment containing extrafine particle beclometasone versus fine particle fluticasoneen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.2147/COPD.S342357
dc.identifier.iss17en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record